These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29227461)

  • 41. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.
    Cressey TR; Jourdain G; Rawangban B; Varadisai S; Kongpanichkul R; Sabsanong P; Yuthavisuthi P; Chirayus S; Ngo-Giang-Huong N; Voramongkol N; Pattarakulwanich S; Lallemant M;
    AIDS; 2010 Sep; 24(14):2193-200. PubMed ID: 20625263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.
    Fauchet F; Treluyer JM; Illamola SM; Pressiat C; Lui G; Valade E; Mandelbrot L; Lechedanec J; Delmas S; Blanche S; Warszawski J; Urien S; Tubiana R; Hirt D
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5727-35. PubMed ID: 26149996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.
    Santini-Oliveira M; Estrela Rde C; Veloso VG; Cattani VB; Yanavich C; Velasque L; Torres TS; Marins LM; Pilotto JH; João EC; Gonçalves JC; Grinsztejn B
    Antimicrob Agents Chemother; 2014 May; 58(5):2884-93. PubMed ID: 24614377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
    PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change.
    Jacobs TG; Mumbiro V; Chitsamatanga M; Namuziya N; Passanduca A; Domínguez-Rodríguez S; Tagarro A; Nathoo KJ; Nduna B; Ballesteros A; Madrid L; Mujuru HA; Chabala C; Buck WC; Rojo P; Burger DM; Moraleda C; Colbers A; ;
    J Acquir Immune Defic Syndr; 2023 May; 93(1):42-46. PubMed ID: 36724434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children.
    Foissac F; Urien S; Hirt D; Frange P; Chaix ML; Treluyer JM; Blanche S
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4320-5. PubMed ID: 21746952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.
    Rakhmanina N; van den Anker J; Baghdassarian A; Soldin S; Williams K; Neely MN
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2532-8. PubMed ID: 19258274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.
    Bellusci CP; Rocco C; Aulicino P; Mecikovsky D; Curras V; Hegoburu S; Bramuglia GF; Bologna R; Sen L; Mangano A
    Gene; 2013 Jun; 522(1):96-101. PubMed ID: 23528223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir.
    Estripeaut D; Mosser J; Doherty M; Acosta W; Shah H; Castaño E; Luciani K; Pascale JM; Bollinger RC; Page KR
    Pediatr Infect Dis J; 2013 Dec; 32(12):e466-72. PubMed ID: 23799516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
    Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
    Camacho Á; Rivero A
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.
    Zhang C; Denti P; Decloedt EH; Ren Y; Karlsson MO; McIlleron H
    Br J Clin Pharmacol; 2013 Nov; 76(5):741-51. PubMed ID: 23432610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.
    Chen J; Malone S; Prince HM; Patterson KB; Dumond JB
    CPT Pharmacometrics Syst Pharmacol; 2016 Mar; 5(3):147-57. PubMed ID: 27069778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers.
    Calderón MM; Chairez CL; Gordon LA; Alfaro RM; Kovacs JA; Penzak SR
    Pharmacotherapy; 2014 Nov; 34(11):1151-8. PubMed ID: 25142999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
    Ramautarsing RA; van der Lugt J; Gorowara M; Wongsabut J; Khongpetch C; Phanuphak P; Ananworanich J; Lange JM; Burger DM; Ruxrungtham K; Avihingsanon A
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):55-8. PubMed ID: 22027875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.